Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on May 13, 2019, reporting events occurring on May 10, 2019. The registrant is a Delaware corporation with its principal executive offices in Livonia, Michigan. The company is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin figures. However, it references the following financial condition:
- Stockholders' Equity: As reported in the 2018 Form 10-K, equity fell below the $10 million threshold required for the Nasdaq Global Market.
- Listing Requirement: The company met the $2.5 million minimum stockholders' equity requirement for the Nasdaq Capital Market.
Material Changes
The primary material change is the transfer of the company's common stock listing:
- Previous Status: Listed on the Nasdaq Global Market.
- Reason for Change: Failure to meet the minimum stockholders' equity requirement ($10 million) for the Global Market.
- New Status: Approved for transfer to the Nasdaq Capital Market, effective May 14, 2019.
- Trading Symbol: The stock will continue to trade under the symbol "GEMP".
Outlook, Risks, and Management Commentary
Management notes that the Nasdaq Capital Market operates in substantially the same manner as the Global Market, though it has different financial requirements. The company must continue to comply with Nasdaq's corporate governance requirements. No specific forward-looking guidance or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the effective date of the listing transfer (May 14, 2019).
- Confirm the continued trading symbol remains "GEMP".
- Review the 2018 Form 10-K to understand the specific equity shortfall that triggered the delisting notice.
- Monitor future filings for compliance with Nasdaq Capital Market corporate governance standards.